Biotech

All Articles

A deeper check out Brutal Biotech's Ferocious 15

.In this particular full week's episode of "The Best Line," our company are actually diving right in...

Lilly encounters phase 2 failure of tau-targeting med

.The confetti is still soaring from Eli Lilly's party commemorating the approval of Alzheimer's illn...

Biogen CMO Maha Radhakrishnan participates in Sofinnova-- Chutes &amp Ladders

.Welcome to this week's Chutes &amp Ladders, our roundup of substantial management hirings, shooting...

Lykos will certainly inquire FDA to reassess its selection observing being rejected of MDMA therapy for trauma

.Following an unsatisfactory revealing for Lykos Therapeutics' MDMA candidate for trauma at a recent...

AN 2 fifty percents census, ceases phase 3 trial after information dissatisfy

.AN2 Therapies is actually reviewing its own service in response to lackluster midphase information,...

Merck spends $700M for bispecific, spying autoimmune opening and opportunity to test Amgen in cancer cells

.Merck &amp Co. is actually paying for $700 thousand in advance to test Amgen in a blood cancer mark...

Gilead spends J&ampJ $320M to go out licensing bargain for seladelpar

.Along With Gilead Sciences almost an FDA choice for its liver health condition medicine seladelpar,...

' All palms on deck' at Lilly as peers target excessive weight market

.Chief executive officer David Ricks can observe the providers setting up outdoors tents at basecamp...

Entero laying off team, abandoning workplace as well as stopping R&ampD

.Bed mattress Liquidators has actually turned Entero Therapeutics white as a sheet. The financial in...

Exelixis drops ADC after choosing it is actually no match for Tivdak

.Exelixis is giving up on its own tissue element (TF)- targeting antibody-drug conjugate after endin...